被搁置了10年的埃博拉病毒疫苗_BEC初级作文

被搁置了10年的埃博拉病毒疫苗

"The National Institutes of Health came up with a program called Partnerships in Biodefense that partnered researchers like me with companies, usually small companies," Dr. Geisbert said.

盖斯伯特博士说，“国立卫生研究院推出了一个叫作生物防御合作(Partnerships in Biodefense)的计划，推动像我这样的研究人员与公司的合作，通常是些小公司。”

The government money led to major advances in the laboratory, Dr. Geisbert said, but was insufficient to cover the huge costs of human trials. Nor could the small companies that were involved in the early studies in animals afford to pay for human trials. No finished product came to market.

盖斯伯特博士表示，政府的资助促使该实验室取得重大进展，但这些资金不足以支付人体试验所需要的巨额费用。那些参与动物试验早期研究的小公司也无法支付人体试验的费用。目前还没有成品上市。

Dr. Geisbert moved on, working on treatments for Ebola and another version of the V.S.V. vaccine. For the vaccine work, his main collaborator has been Dr. Heinz Feldmann, the chief of virology at the Rocky Mountain Laboratories in Hamilton, Mont., part of the National Institute of Allergy and Infectious Diseases.

盖斯波特博士继续研究埃博拉的治疗方法，以及另一种VSV疫苗。在疫苗研制工作方面，他的主要合作伙伴是蒙大拿州哈密尔顿落基山实验室(Rocky Mountain Laboratories)的首席病毒专家海因茨·费尔德曼(Heinz Feldmann)。落基山实验室隶属于美国国家过敏及传染性疾病研究所(National Institute of Allergy and Infectious Diseases)。